EUVIMEDEUVIMED entdecken
Crossref

Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies

A C Franke, D Jung, T M Ellis

Hybridoma · 2000

DOI: 10.1089/027245700315789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hybridoma, 2000. Verfasst von A C Franke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University School of Medicine, Maywood, IL 60153, USA. Hauptthemen laut MEDLINE: Binding Sites, Antibody. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation. Several monoclonal antibodies (MAbs) have been developed against CD30 and, based on mutual inhibition assays, are grouped into three nonoverlapping serologic clusters. However, the relationship between the epitopes recognized by the antibodies comprising each cluster and the binding domain for CD30L is not known. Using a soluble CD30L/CD8alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30+ Karpas 299 cell line. CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44). Cluster Group B antibodies, including M67 and Ki-1, do not affect CD30L binding to CD30. The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling. Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction. This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Binding Sites, AntibodyAntibodies, MonoclonalBinding, CompetitiveCD30 LigandCD8 AntigensCell LineCell Line, TransformedHumansKi-1 AntigenLigandsMembrane GlycoproteinsProtein BindingProtein Structure, TertiaryRecombinant Fusion ProteinsTumor Cells, Cultured

Substanzen

Antibodies, MonoclonalCD30 LigandCD8 AntigensKi-1 AntigenLigandsMembrane GlycoproteinsRecombinant Fusion ProteinsTNFSF8 protein, human

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University School of Medicine, Maywood, IL 60153, USA.

Zitieren

APA

Franke, A. C., Jung, D., & Ellis, T. M. (2000). Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies. Hybridoma. https://doi.org/10.1089/027245700315789

Vancouver

Franke AC, Jung D, Ellis TM. Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies. Hybridoma. 2000. doi:10.1089/027245700315789

BibTeX
@article{Franke2000,
  author = {Franke, A C and Jung, D and Ellis, T M},
  title = {Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies},
  journal = {Hybridoma},
  year = {2000},
  doi = {10.1089/027245700315789}
}
Kostenlos starten →